Charles J Glueck

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6191732/publications.pdf

Version: 2024-02-01

199 papers 9,810 citations

23567 58 h-index 91 g-index

201 all docs

201 docs citations

times ranked

201

6189 citing authors

#	Article	IF	CITATIONS
1	Long-term Anticoagulation Prevents Progression of Stages I and II Primary Osteonecrosis of the Hip in Patients With Familial Thrombophilia. Orthopedics, 2020, 43, e208-e214.	1.1	9
2	Testosterone Therapy, Thrombophilia, Venous Thromboembolism, and Thrombotic Events. Journal of Clinical Medicine, 2019, 8, 11.	2.4	27
3	Characteristics of obesity in polycystic ovary syndrome: Etiology, treatment, and genetics. Metabolism: Clinical and Experimental, 2019, 92, 108-120.	3.4	215
4	Alirocumab in high-risk patients: Observations from the open-label expanded use program. Journal of Clinical Lipidology, 2018, 12, 662-668.	1.5	12
5	Thrombophilia in 153 Patients With Premature Cardiovascular Disease â‰ ¤ ge 45. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 295-302.	1.7	9
6	Thromboembolism Peaking 3 Months after Starting Testosterone Therapy: Testosterone–Thrombophilia Interactions. Journal of Investigative Medicine, 2018, 66, 733-738.	1.6	6
7	Efficacy, safety, Low density lipoprotein cholesterol lowering, and calculated 10-year cardiovascular risk reduction of alirocumab and evolocumab in addition to maximal tolerated cholesterol lowering therapy: a post-commercialization study. Lipids in Health and Disease, 2017, 16, 19.	3.0	9
8	Progressively Worsening Premature Coronary Artery Disease: Adding Anticoagulation Stabilizesâ€"Reverses Clinical Symptomatic Disease Progression in Thrombophilicâ€"Atherothrombotic Patients: A Pilot Study. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 1060-1070.	1.7	0
9	Osteonecrosis and Thrombophilia: Pathophysiology, Diagnosis, and Treatment., 2017,, 3-17.		1
10	Low serum vitamin D, statin associated muscle symptoms, vitamin D supplementation. Atherosclerosis, 2017, 256, 125-127.	0.8	15
11	Case report: primary osteonecrosis associated with thrombophilia-hypofibrinolysis and worsened by testosterone therapy. BMC Hematology, 2017, 17, 5.	2.6	11
12	Thrombophilia in Klinefelter Syndrome With Deep Venous Thrombosis, Pulmonary Embolism, and Mesenteric Artery Thrombosis on Testosterone Therapy: A Pilot Study. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 973-979.	1.7	19
13	Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy. Vascular Health and Risk Management, 2017, Volume 13, 247-253.	2.3	2
14	Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study. Lipids in Health and Disease, 2017, 16, 141.	3.0	4
15	T786C Mutation in the Endothelial Nitric Oxide Synthase Gene in Patients With Primary Osteonecrosis. Orthopedics, 2017, 40, e898-e903.	1.1	3
16	Retinal artery and vein thrombotic occlusion during pregnancy: markers for familial thrombophilia and adverse pregnancy outcomes. Clinical Ophthalmology, 2016, 10, 935.	1.8	19
17	Retinal vascular occlusion: a window to diagnosis of familial and acquired thrombophilia and hypofibrinolysis, with important ramifications for pregnancy outcomes. Clinical Ophthalmology, 2016, Volume 10, 1479-1486.	1.8	6
18	Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center. Lipids in Health and Disease, 2016, 15, 132.	3.0	14

#	Article	IF	CITATIONS
19	Four Thrombotic Events Over 5 Years, Two Pulmonary Emboli and Two Deep Venous Thrombosis, When Testosterone-HCG Therapy Was Continued Despite Concurrent Anticoagulation in a 55-Year-Old Man With Lupus Anticoagulant. Journal of Investigative Medicine High Impact Case Reports, 2016, 4, 232470961666183.	0.6	5
20	Hospitalization for pulmonary embolism associated with antecedent testosterone or estrogen therapy in patients found to have familial and acquired thrombophilia. BMC Hematology, 2016, 16, 6.	2.6	10
21	Thrombophilia in 67 Patients With Thrombotic Events After Starting Testosterone Therapy. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 548-553.	1.7	34
22	Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70Âmg/dl despite maximal tolerated cholesterol lowering therapy. Lipids in Health and Disease, 2016, 15, 55.	3.0	15
23	Venous Thromboembolism After Knee Arthroscopy in Undiagnosed Familial Thrombophilia. Orthopedics, 2016, 39, e1052-e1057.	1.1	5
24	Safety of 50,000-100,000 units of vitamin D3/week in vitamin D-deficient, hypercholesterolemic patients with reversible statin intolerance. North American Journal of Medical Sciences, 2016, 8, 156.	1.7	22
25	Treatable high homocysteine alone or in concert with five other thrombophilias in 1014 patients with thrombotic events. Blood Coagulation and Fibrinolysis, 2015, 26, 736-742.	1.0	7
26	Diagnostic ramifications of ocular vascular occlusion as a first thrombotic event associated with factor V Leiden and prothrombin gene heterozygosity. Clinical Ophthalmology, 2015, 9, 591.	1.8	20
27	Long Term Anticoagulation (4–16 Years) Stops Progression of Idiopathic Hip Osteonecrosis Associated with Familial Thrombophilia. Advances in Orthopedics, 2015, 2015, 1-7.	1.0	23
28	Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy. Mayo Clinic Proceedings, 2015, 90, 1038-1045.	3.0	90
29	The eNOS T786C mutation, Prinzmetal's Variant Angina, and amelioration of angina by l-arginine in 59 patients with intractable angina despite calcium channel blocker–nitrate therapy. IJC Metabolic & Endocrine, 2015, 8, 13-19.	0.5	1
30	Adolescent and Young Adult Female Determinants of Visceral Adipose Tissue at Ages 26-28 Years. Journal of Pediatrics, 2015, 166, 936-946.e3.	1.8	8
31	Testosterone, thrombophilia, thrombosis. Translational Research, 2015, 165, 537-548.	5.0	33
32	Adolescent Oligomenorrhea (Age 14–19) Tracks Into the Third Decade of Life (Age 20–28) and Predicts Increased Cardiovascular Risk Factors and Metabolic Syndrome. Metabolism: Clinical and Experimental, 2015, 64, 539-553.	3.4	27
33	Statin intolerance because of myalgia, myositis, myopathy, or myonecrosis can in most cases be safely resolved by vitamin d supplementation. North American Journal of Medical Sciences, 2015, 7, 86.	1.7	83
34	Testosterone therapy, thrombophilia, and hospitalization for deep venous thrombosis–pulmonary embolus, an exploratory, hypothesis-generating study. Medical Hypotheses, 2015, 84, 341-343.	1.5	8
35	Age of Menarche and Oligomenorrhea in Adolescence: Cardiometabolic Ramifications in Adulthood. Journal of Pediatrics, 2015, 167, 225-227.	1.8	2
36	Testosterone Therapy Can Interact With Thrombophilia, Leading to Osteonecrosis. Orthopedics, 2015, 38, e1073-8.	1.1	10

#	Article	IF	CITATIONS
37	Statin Intolerance and Vitamin D Supplementation. North American Journal of Medical Sciences, 2015, 7, 339-40.	1.7	2
38	Testosterone, Thrombophilia, and Thrombosis. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 22-30.	1.7	27
39	Testosterone, thrombophilia, thrombosis. Blood Coagulation and Fibrinolysis, 2014, 25, 683-687.	1.0	21
40	Testosterone, anastrozole, factor V Leiden heterozygosity and osteonecrosis of the jaws. Blood Coagulation and Fibrinolysis, 2014, 25, 286-288.	1.0	14
41	Testosterone therapy, thrombosis, thrombophilia, cardiovascular events. Metabolism: Clinical and Experimental, 2014, 63, 989-994.	3.4	60
42	Testosterone Therapy, Thrombophilia–Hypofibrinolysis, and Hospitalization for Deep Venous Thrombosis-Pulmonary Embolus. Clinical and Applied Thrombosis/Hemostasis, 2014, 20, 244-249.	1.7	35
43	Medical Treatment of Osteonecrosis of the Knee Associated With Thrombophilia-Hypofibrinolysis. Orthopedics, 2014, 37, e911-6.	1.1	15
44	Treatment of Osteonecrosis of the Hip and Knee with Enoxaparin. , 2014, , 241-247.		5
45	The endothelial nitric oxide synthase T-786c mutation, a treatable etiology of Prinzmetal's angina. Translational Research, 2013, 162, 64-66.	5.0	15
46	Does low serum 25 OH vitamin D interact with very strenuous physical activity, facilitating development of rhabdomyolysis?. Medical Hypotheses, 2013, 81, 551-552.	1.5	0
47	Early and late menarche are associated with oligomenorrhea and predict metabolic syndrome 26years later. Metabolism: Clinical and Experimental, 2013, 62, 1597-1606.	3.4	48
48	Effects of metformin-diet intervention before and throughout pregnancy on obstetric and neonatal outcomes in patients with polycystic ovary syndrome. Current Medical Research and Opinion, 2013, 29, 55-62.	1.9	34
49	Thrombosis in Three Postmenopausal Women Receiving Testosterone Therapy for Low Libido. Women's Health, 2013, 9, 405-410.	1.5	21
50	The Role of the Factor V Leiden Mutation in Osteonecrosis of the Hip. Clinical and Applied Thrombosis/Hemostasis, 2013, 19, 499-503.	1.7	31
51	Severe vitamin D deficiency, myopathy, and rhabdomyolysis. North American Journal of Medical Sciences, 2013, 5, 494.	1.7	9
52	Determinants of ApoB, ApoA1, and the ApoB/ApoA1 ratio in healthy schoolgirls, prospectively studied from mean ages 10 to 19 years: the Cincinnati National Growth and Health Study. Metabolism: Clinical and Experimental, 2012, 61, 1377-1387.	3.4	10
53	Risk factors for cardiovascular disease and type 2 diabetes retained from childhood to adulthood predict adult outcomes: the Princeton LRC Follow-up Study. International Journal of Pediatric Endocrinology (Springer), 2012, 2012, 6.	1.6	64
54	Titrating lovaza from 4 to 8 to 12 grams/day in patients with primary hypertriglyceridemia who had triglyceride levels >500 mg/dl despite conventional triglyceride lowering therapy. Lipids in Health and Disease, 2012, 11, 143.	3.0	14

#	Article	IF	Citations
55	Thrombophilia and retinal vascular occlusion. Clinical Ophthalmology, 2012, 6, 1377.	1.8	38
56	Race, Childhood Insulin, Childhood Caloric Intake, and Class 3 Obesity at Age 24: 14‥ear Prospective Study of Schoolgirls. Obesity, 2012, 20, 597-604.	3.0	4
57	The Child as Proband for Future Parental Cardiometabolic Disease: The 26-Year Prospective Princeton Lipid Research Clinics Follow-Up Study. Journal of Pediatrics, 2012, 160, 590-597.e3.	1.8	8
58	Childhood risk factors predict cardiovascular disease, impaired fasting glucose plus type 2 diabetes mellitus, and high blood pressure 26 years later at a mean age of 38 years: the Princeton–lipid research clinics follow-up study. Metabolism: Clinical and Experimental, 2012, 61, 531-541.	3.4	84
59	Vitamin D deficiency, myositis–myalgia, and reversible statin intolerance. Current Medical Research and Opinion, 2011, 27, 1683-1690.	1.9	77
60	Successful anticoagulation for bilateral central retinal vein occlusion. Clinica Chimica Acta, 2011, 412, 1165-1166.	1.1	1
61	Ramifications of adolescent menstrual cycles ≥42 days in young adults. Fertility and Sterility, 2011, 96, 236-240.e1.	1.0	8
62	Symptomatic myositis-myalgia in hypercholesterolemic statin-treated patients with concurrent vitamin D deficiency leading to statin intolerance may reflect a reversible interaction between vitamin D deficiency and statins on skeletal muscle. Medical Hypotheses, 2011, 77, 658-661.	1.5	31
63	Thrombotic events after starting exogenous testosterone in men with previously undiagnosed familial thrombophilia. Translational Research, 2011, 158, 225-234.	5.0	49
64	Hyperinsulinemia and metabolic syndrome at mean age of 10 years in black and white schoolgirls and development of impaired fasting glucose and type 2 diabetes mellitus by mean age of 24 years. Metabolism: Clinical and Experimental, 2011, 60, 24-31.	3.4	31
65	Adolescent oligomenorrhea in a biracial schoolgirl cohort: a simple clinical parameter predicting impaired fasting glucose plus type 2 diabetes mellitus, insulin, glucose, insulin resistance, and centripetal obesity from age 19 to 25 years. Metabolism: Clinical and Experimental, 2011, 60, 1285-1293.	3.4	14
66	Paradoxically High Adiponectin in Obese 16-Year-Old Girls Protects Against Appearance of the Metabolic Syndrome and its Components Seven Years Later. Journal of Pediatrics, 2011, 158, 208-214.e1.	1.8	17
67	Pediatric Non–High-Density Lipoprotein Cholesterol, the Metabolic Syndrome, and Insulin Resistance. Journal of Pediatrics, 2011, 158, 179-181.	1.8	5
68	Sex Hormone-Binding Globulin, Oligomenorrhea, Polycystic Ovary Syndrome, and Childhood Insulin at Age 14 Years Predict Metabolic Syndrome and Class III Obesity at Age 24 Years. Journal of Pediatrics, 2011, 159, 308-313.e2.	1.8	47
69	High-Sensitivity C Reactive Protein: Associations with Cardiovascular Risk Factors and Tracking in Female Adolescents and Young Adults. ISRN Pediatrics, 2011, 2011, 1-9.	1.2	3
70	Childhood Predictors of Adult Type 2 Diabetes at 9- and 26-Year Follow-ups. JAMA Pediatrics, 2010, 164, 53-60.	3.0	74
71	Determinants of Persistent Obesity and Hyperinsulinemia in a Biracial Cohort: A 15-Year Prospective Study of Schoolgirls. Journal of Pediatrics, 2010, 157, 559-565.	1.8	10
72	Preteen insulin levels interact with caloric intake to predict increases in obesity at ages 18 to 19 years: a 10-year prospective study of black and white girls. Metabolism: Clinical and Experimental, 2010, 59, 718-727.	3.4	16

#	Article	IF	CITATIONS
73	Endothelial Nitric Oxide Synthase T-786C Mutation, A Reversible Etiology of Prinzmetal's Angina Pectoris. American Journal of Cardiology, 2010, 105, 792-796.	1.6	18
74	Paradoxically high adiponectin and the healthy obese phenotype in obese black and white 16-year-old girls. Translational Research, 2010, 156, 302-308.	5.0	10
75	High factor XI, recurrent pregnancy loss, enoxaparin. Fertility and Sterility, 2010, 94, 2828-2831.	1.0	7
76	Tâ^'786C polymorphism of the endothelial nitric oxide synthase gene and neuralgia-inducing cavitational osteonecrosis of the jaws. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 2010, 109, 548-553.	1.4	9
77	The Long-Term Metabolic Complications of Childhood Obesity. , 2010, , 253-263.		O
78	Metformin-Diet Ameliorates Coronary Heart Disease Risk Factors and Facilitates Resumption of Regular Menses in Adolescents with Polycystic Ovary Syndrome. Journal of Pediatric Endocrinology and Metabolism, 2009, 22, 815-26.	0.9	6
79	A Likelihood Model That Accounts for Censoring Due to Fetal Loss Can Accurately Test the Effects of Maternal and Fetal Genotype on the Probability of Miscarriage. Human Heredity, 2009, 67, 57-65.	0.8	5
80	Homeostasis model assessment of insulin resistance*body mass index interactions at ages 9 to 10 years predict metabolic syndrome risk factor aggregate score at ages 18 to 19 years: a 10-year prospective study of black and white girls. Metabolism: Clinical and Experimental, 2009, 58, 290-295.	3.4	16
81	VKORC1 Variant Genotypes Influence Warfarin Response in Patients Undergoing Total Joint Arthroplasty: A Pilot Study. Clinical Orthopaedics and Related Research, 2009, 467, 1773-1780.	1.5	8
82	Ocular Vascular Thrombotic Events: A Diagnostic Window to Familial Thrombophilia (Compound) Tj ETQq0 0 0 Thrombosis/Hemostasis, 2009, 15, 12-18.	rgBT /Over 1.7	lock 10 Tf 50 16
83	Should high creatine kinase discourage the initiation or continuance of statins for the treatment of hypercholesterolemia?. Metabolism: Clinical and Experimental, 2009, 58, 233-238.	3.4	21
84	Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with a healthy female population. Metabolism: Clinical and Experimental, 2009, 58, 714-721.	3.4	39
85	Pediatric triglycerides predict cardiovascular disease events in the fourth to fifth decade of life. Metabolism: Clinical and Experimental, 2009, 58, 1277-1284.	3.4	52
86	Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients. Translational Research, 2009, 153, 11-16.	5.0	167
87	Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss. Translational Research, 2009, 153, 33-43.	5.0	19
88	Heritable Thrombophilia-Hypofibrinolysis and Osteonecrosis of the Femoral Head. Clinical Orthopaedics and Related Research, 2008, 466, 1034-1040.	1.5	81
89	Bone Marrow Edema: Mild or Nascent Variant of Ischemic Bone Disease. Journal of Oral and Maxillofacial Surgery, 2008, 66, 205-208.	1.2	6
90	Metabolic Syndrome in Childhood Predicts Adult Metabolic Syndrome and Type 2 Diabetes Mellitus 25 to 30 Years Later. Journal of Pediatrics, 2008, 152, 201-206.	1.8	532

#	Article	IF	CITATIONS
91	An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet. Metabolism: Clinical and Experimental, 2008, 57, 954-960.	3.4	28
92	Factor V Leiden mutation: a treatable etiology for sporadic and recurrent pregnancy loss. Fertility and Sterility, 2008, 89, 410-416.	1.0	28
93	Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome. Fertility and Sterility, 2008, 89, 625-634.	1.0	79
94	Dietary trans fatty acid intake is associated with increased fetal loss. Fertility and Sterility, 2008, 90, 385-390.	1.0	22
95	Insulin Resistance, Obesity, Hypofibrinolysis, Hyperandrogenism, and Coronary Heart Disease Risk Factors in 25 Pre-Perimenarchal Girls Age <14 Years, 13 with Precocious Puberty, 23 with a First-degree Relative with Polycystic Ovary Syndrome. Journal of Pediatric Endocrinology and Metabolism. 2008. 21. 973-84.	0.9	12
96	Is pharmacogenomics our future? Metformin, ovulation and polymorphism of the STK11gene in polycystic ovary syndrome. Pharmacogenomics, 2008, 9, 1163-1165.	1.3	12
97	Ocular Vascular Thrombotic Events: Central Retinal Vein and Central Retinal Artery Occlusions. Clinical and Applied Thrombosis/Hemostasis, 2008, 14, 286-294.	1.7	48
98	Thrombophilia, Hypofibrinolysis, the eNOS T-786C Polymorphism, and Multifocal Osteonecrosis. Journal of Bone and Joint Surgery - Series A, 2008, 90, 2220-2229.	3.0	64
99	Pre-teen insulin resistance predicts weight gain, impaired fasting glucose, and type 2 diabetes at age 18–19 y: a 10-y prospective study of black and white girls. American Journal of Clinical Nutrition, 2008, 88, 778-788.	4.7	79
100	Association Between the T-786C eNOS Polymorphism and Idiopathic Osteonecrosis of the Head of the Femur. Journal of Bone and Joint Surgery - Series A, 2007, 89, 2460-2468.	3.0	35
101	Amaurosis Fugax Caused by Heritable Thrombophilia-Hypofibrinolysis in Cases Without Carotid Atherosclerosis. Clinical and Applied Thrombosis/Hemostasis, 2007, 13, 124-129.	1.7	6
102	Legg-Calve-Perthes Disease, Venous and Arterial Thrombi, and the Factor V Leiden Mutation in a Four-Generation Kindred. Journal of Pediatric Orthopaedics, 2007, 27, 834-837.	1.2	11
103	Metformin before and during pregnancy and lactation in polycystic ovary syndrome. Expert Opinion on Drug Safety, 2007, 6, 191-198.	2.4	34
104	Thrombophilia–hypofibrinolysis and atherothrombotic cardiovascular disease ≤ge 45 years. Translational Research, 2007, 150, 93-100.	5.0	14
105	Staging Bisphosphonate-Related Osteonecrosis of the Jaw Should Include Early Stages of Disease. Journal of Oral and Maxillofacial Surgery, 2007, 65, 1899-1900.	1.2	21
106	Detecting Thrombophilia, Hypofibrinolysis and Reduced Nitric Oxide Production in Osteonecrosis. Seminars in Arthroplasty, 2007, 18, 184-191.	0.7	9
107	Association Between the T-786C eNOS Polymorphism and Idiopathic Osteonecrosis of the Head of the Femur. Journal of Bone and Joint Surgery - Series A, 2007, 89, 2460-2468.	3.0	21
108	Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism: Clinical and Experimental, 2006, 55, 345-352.	3.4	59

#	Article	IF	CITATIONS
109	Obesity, free testosterone, and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents. Metabolism: Clinical and Experimental, 2006, 55, 508-514.	3.4	56
110	Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndrome. Metabolism: Clinical and Experimental, 2006, 55, 1582-1589.	3.4	36
111	Changes in weight, papilledema, headache, visual field, and life status in response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia. Translational Research, 2006, 148, 215-222.	5.0	23
112	Stromelysin-1 5A/6A and eNOS T-786C Polymorphisms, MTHFR C677T and A1298C Mutations, and Cigarette-Cannabis Smoking: A Pilot, Hypothesis-Generating Study of Gene-Environment Pathophysiological Associations With Buerger's Disease. Clinical and Applied Thrombosis/Hemostasis, 2006, 12, 427-439.	1.7	24
113	Rosuvastatin 5 and 10 mg/d: A pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach ldl cholesterol goals with nonstatin lipid-lowering therapies. Clinical Therapeutics, 2006 , 28 , $933-942$.	2.5	62
114	Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome. Journal of Pediatrics, 2006, 148, 628-632.e2.	1.8	47
115	Beyond bisphosphonates: Thrombophilia, hypofibrinolysis, and jaw osteonecrosis. Journal of Oral and Maxillofacial Surgery, 2006, 64, 1704-1705.	1.2	6
116	Interaction of Duloxetine and Warfarin Causing Severe Elevation of International Normalized Ratio. JAMA - Journal of the American Medical Association, 2006, 295, 1513.	7.4	32
117	Enoxaparin Prevents Progression of Stages I and II Osteonecrosis of the Hip. Clinical Orthopaedics and Related Research, 2005, &NA, 164-170.	1.5	163
118	THE JOHN CHARNLEY AWARD: Heritable Thrombophilia and Development of Thromboembolic Disease after Total Hip Arthroplasty. Clinical Orthopaedics and Related Research, 2005, 441, 40-55.	1.5	45
119	Idiopathic intracranial hypertension, polycystic-ovary syndrome, and thrombophilia. Translational Research, 2005, 145, 72-82.	2.3	104
120	Metformin-diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance. Metabolism: Clinical and Experimental, 2005, 54, 113-121.	3.4	31
121	Obesity and extreme obesity, manifest by ages 20–24 years, continuing through 32–41 years in women, should alert physicians to the diagnostic likelihood of polycystic ovary syndrome as a reversible underlying endocrinopathy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2005, 122, 206-212.	1.1	88
122	The factor V Leiden mutation, high factor VIII, and high plasminogen activator inhibitor activity: etiologies for sporadic miscarriage. Metabolism: Clinical and Experimental, 2005, 54, 1345-1349.	3.4	25
123	Associations of Thrombophilia, Hypofibrinolysis, and Retinal Vein Occlusion. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 375-389.	1.7	44
124	Idiopathic Intracranial Hypertension: Associations with Thrombophilia and Hypofibrinolysis in Men. Clinical and Applied Thrombosis/Hemostasis, 2005, 11, 441-448.	1.7	17
125	Response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia. MedGenMed: Medscape General Medicine, 2005, 7, 41.	0.2	0
126	Ramifications of Four Concurrent Thrombophilic Mutations and One Hypofibrinolytic Mutation. Clinical and Applied Thrombosis/Hemostasis, 2004, 10, 365-371.	1.7	4

#	Article	lF	Citations
127	Osteonecrosis: a multifactorial etiology. Journal of Oral and Maxillofacial Surgery, 2004, 62, 904-905.	1.2	27
128	Nonarteritic anterior ischemic optic neuropathy: associations with homozygosity for the C677T methylenetetrahydrofolate reductase mutation. Translational Research, 2004, 143, 184-192.	2.3	61
129	Pregnancy Loss, Polycystic Ovary Syndrome, Thrombophilia, Hypofibrinolysis, Enoxaparin, Metformin. Clinical and Applied Thrombosis/Hemostasis, 2004, 10, 323-334.	1.7	62
130	Population-specific alleles: the polymorphism (k121q) of the human glycoprotein PC-1 gene is strongly associated with race but not with insulin resistance in black and white children. Metabolism: Clinical and Experimental, 2004, 53, 465-468.	3 . 4	27
131	Risk Factors for Pulmonary Emboli after Total Hip or Knee Arthroplasty. Clinical Orthopaedics and Related Research, 2004, 422, 154-163.	1.5	36
132	LEGG-CALVÉ-PERTHES DISEASE AND THROMBOPHILIA. Journal of Bone and Joint Surgery - Series A, 2004, 86, 2642-2647.	3.0	96
133	Metformin and gestational diabetes. Current Diabetes Reports, 2003, 3, 303-312.	4.2	37
134	Idiopathic intracranial hypertension: associations with coagulation disorders and polycystic-ovary syndrome. Translational Research, 2003, 142, 35-45.	2.3	87
135	Polycystic ovary syndrome, the G1691A factor V Leiden mutation, and plasminogen activator inhibitor activity: associations with recurrent pregnancy loss. Metabolism: Clinical and Experimental, 2003, 52, 1627-1632.	3.4	50
136	An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia. Clinica Chimica Acta, 2003, 332, 11-19.	1.1	50
137	Pioglitazone and metformin in obese women with polycystic ovary syndrome not optimally responsive to metformin. Human Reproduction, 2003, 18, 1618-1625.	0.9	99
138	Procoagulants and osteonecrosis. Journal of Rheumatology, 2003, 30, 783-91.	2.0	124
139	Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opinion on Pharmacotherapy, 2002, 3, 1177-1189.	1.8	48
140	Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Human Reproduction, 2002, 17, 2858-2864.	0.9	338
141	The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin. Expert Opinion on Pharmacotherapy, 2002, 3, 1557-1568.	1.8	36
142	Estrogen replacement therapy, thrombophilia, and atherothrombosis. Metabolism: Clinical and Experimental, 2002, 51, 724-732.	3.4	15
143	CORRELATION OF THROMBOPHILIA AND HYPOFIBRINOLYSIS WITH PULMONARY EMBOLISM FOLLOWING TOTAL HIP ARTHROPLASTY. Journal of Bone and Joint Surgery - Series A, 2002, 84, 2161-2167.	3.0	57
144	Genetic hypofibrinolysis in complicated pregnancies. Obstetrics and Gynecology, 2001, 97, 44-48.	2.4	70

#	Article	IF	Citations
145	Interaction of Heritable and Estrogen-induced Thrombophilia: Possible Etiologies for Ischemic Optic Neuropathy and Ischemic Stroke. Thrombosis and Haemostasis, 2001, 85, 256-259.	3.4	21
146	Hypofibrinolysis, Thrombophilia, Osteonecrosis. Clinical Orthopaedics and Related Research, 2001, 386, 19-33.	1.5	194
147	Genetic Hypofibrinolysis in Complicated Pregnancies. Obstetrics and Gynecology, 2001, 97, 44-48.	2.4	47
148	Anticoagulant therapy for osteonecrosis associated with heritable hypofibrinolysis and thrombophilia. Expert Opinion on Investigational Drugs, 2001, 10, 1309-1316.	4.1	28
149	The Relationship of Mutations in the MTHFR, Prothrombin, and PAI-1 Genes to Plasma Levels of Homocysteine, Prothrombin, and PAI-1 in Children and Adults. Thrombosis and Haemostasis, 1999, 81, 739-744.	3.4	125
150	Heritable Thrombophilia and Hypofibrinolysis. JAMA Ophthalmology, 1999, 117, 43.	2.4	93
151	Evidence that anticardiolipin antibodies are independent risk factors for atherosclerotic vascular disease. American Journal of Cardiology, 1999, 83, 1490-1494.	1.6	29
152	Contribution of fasting hyperinsulinemia to prediction of atherosclerotic cardiovascular disease status in 293 hyperlipidemic patients. Metabolism: Clinical and Experimental, 1999, 48, 1437-1444.	3.4	20
153	The Plasminogen Activator Inhibitor-1 Gene, Hypofibrinolysis, and Osteonecrosis. Clinical Orthopaedics and Related Research, 1999, 366, 133-146.	1.5	118
154	Legg-Perthes disease in three siblings, two heterozygous and one homozygous for the factor ν Leiden mutation. Journal of Pediatrics, 1998, 132, 885-888.	1.8	48
155	Prospective Assessment of Coronary Heart Disease Risk Factors: The NHANES I Epidemiologic Follow-up Study (NHEFS) 16-Year Follow-up. Journal of the American College of Nutrition, 1998, 17, 263-269.	1.8	55
156	Exogenous Estrogen May Exacerbate Thrombophilia, Impair Bone Healing and Contribute to Development of Chronic Facial Pain. Cranio - Journal of Craniomandibular Practice, 1998, 16, 143-153.	1.4	13
157	Thrombophilia and Hypofibrinolysis; Pathophysiologies of Osteonecrosis. Clinical Orthopaedics and Related Research, 1997, 334, 43???56.	1.5	146
158	Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism: Clinical and Experimental, 1997, 46, 454-457.	3.4	258
159	Heterozygosity for the leiden mutation of the factor v gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens. Translational Research, 1997, 130, 540-543.	2.3	49
160	Resistance to Activated Protein C and Legg-Perthes Disease. Clinical Orthopaedics and Related Research, 1997, 338, 139-152.	1.5	80
161	Familial Heterozygous Protein-S Deficiency in a Patient Who Had Multifocal Osteonecrosis. A Case Report*. Journal of Bone and Joint Surgery - Series A, 1997, 79, 1079-84.	3.0	50
162	Thrombophilia, hypofibrinolysis, and alveolar osteonecrosis of the jaws. Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics, 1996, 81, 557-566.	1.4	54

#	Article	IF	CITATIONS
163	The pathophysiology of alveolar osteonecrosis of the jaw: Anticardiolipin antibodies, thrombophilia, and hypofibrinolysis. Translational Research, 1996, 127, 481-488.	2.3	66
164	Treatment of severe familial hypertriglyceridemia during pregnancy with very-low-fat diet and n-3 fatty acids. Nutrition, 1996, 12, 202-205.	2.4	22
165	Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. American Journal of Cardiology, 1995, 75, 132-136.	1.6	142
166	Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with stanozolol. American Journal of Hematology, 1995, 48, 213-220.	4.1	81
167	Protein C and S Deficiency, Thrombophilia, and Hypofibrinolysis: Pathophysiologic Causes of Legg-Perthes Disease. Pediatric Research, 1994, 35, 383-388.	2.3	102
168	Hypofibrinolysis: A common, major cause of osteonecrosis. American Journal of Hematology, 1994, 45, 156-166.	4.1	115
169	Hypocholesterolemia and Affective Disorders. American Journal of the Medical Sciences, 1994, 308, 218-225.	1.1	71
170	Relationships between lipoprotein(a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators, and d-dimer. Metabolism: Clinical and Experimental, 1993, 42, 236-246.	3.4	88
171	Low or lowered cholesterol and risk of death from suicide and trauma. Metabolism: Clinical and Experimental, 1993, 42, 45-56.	3.4	86
172	Relationships of serum plant sterols (phytosterols) and cholesterol in 595 hypercholesterolemic subjects, and familial aggregation of phytosterols, cholesterol, and premature coronary heart disease in hyperphytosterolemic probands and their first-degree relatives. Metabolism: Clinical and Experimental, 1991, 40, 842-848.	3.4	184
173	FATNESS AND FAT PATTERNS: ASSOCIATIONS WITH PLASMA LIPIDS AND BLOOD PRESSURES IN ADULTS, 18 TO 57 YEARS OF AGE1. American Journal of Epidemiology, 1987, 126, 614-628.	3.4	105
174	Apolipoprotein A-I Gene Polymorphism Associated with Premature Coronary Artery Disease and Familial Hypoalphalipoproteinemia. New England Journal of Medicine, 1986, 314, 671-677.	27.0	213
175	Blood Lead Levels and Dietary Calcium Intake in 1- to 11-Year-Old Children: The Second National Health and Nutrition Examination Survey, 1976 to 1980. Pediatrics, 1986, 78, 257-262.	2.1	118
176	A multivariate analysis of familial associations of lipoprotein levels in the Lipid Research Clinics Collaborative Family Study: I. Familial correlation and regression analyses. Genetic Epidemiology, 1985, 2, 283-300.	1.3	4
177	Determinants of high-density lipoprotein cholesterol in blacks and whites: The second National Health and Nutrition Examination Survey. American Heart Journal, 1984, 108, 641-653.	2.7	73
178	Severe depression of high-density lipoprotein cholesterol levels in weight lifters and body builders by self-administered exogenous testosterone and anabolic-androgenic steroids. Metabolism: Clinical and Experimental, 1984, 33, 971-975.	3.4	125
179	Selected Nutrient Intakes of Free-Living White Children Ages 6–19 Years. The Lipid Research Clinics Program Prevalence Study(40, 41). Pediatric Research, 1983, 17, 124-130.	2.3	20
180	PARENT-CHILD CORONARY HEART DISEASE RISK FACTOR ASSOCIATIONS. American Journal of Epidemiology, 1981, 114, 827-835.	3.4	11

#	Article	IF	CITATIONS
181	CLUSTERING AND INTERRELATIONSHIPS OF CORONARY HEART DISEASE RISK FACTORS IN SCHOOLCHILDREN, AGES 6–19. American Journal of Epidemiology, 1980, 112, 524-538.	3.4	84
182	METABOLIC CONSEQUENCES OF EXPOSURE TO POLYCHLORINATED BIPHENYLS (PCB) IN SEWAGE SLUDGE. American Journal of Epidemiology, 1980, 112, 553-563.	3.4	113
183	RELATIONSHIPS OF MEASUREMENTS OF BODY MASS TO PLASMA LIPOPROTEINS IN SCHOOLCHILDREN AND ADULTS. American Journal of Epidemiology, 1980, 111, 395-406.	3.4	104
184	Effects of diet and high density lipoprotein subfractions on the removal of cellular cholesterol. Lipids, 1980, 15, 230-235.	1.7	16
185	Plasma Cholesterol and Triglyceride Distributions in 13,665 Children and Adolescents: the Prevalence Study of the Lipid Research Clinics Program. Pediatric Research, 1980, 14, 194-202.	2.3	115
186	Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemia. Metabolism: Clinical and Experimental, 1980, 29, 956-964.	3.4	89
187	Intrafamilial associations of cholesterol and triglyceride among related and unrelated household members. Clinical Genetics, 1980, 18, 321-328.	2.0	13
188	High and low density lipoprotein cholesterol levels in hypercholesterolemic school children. Lipids, 1979, 14, 99-104.	1.7	19
189	Lipids, lipoproteins, and sexual maturation during adolescence: The princeton maturation study. Metabolism: Clinical and Experimental, 1979, 28, 641-649.	3.4	131
190	LIPID AND LIPOPROTEIN TRACKING IN CHILDREN. Pediatric Research, 1979, 13, 1082-1084.	2.3	9
191	Plasma 25-Hydroxy-vitamin D in Familial Hypercholesterolemic Children Receiving Colestipol Resin. Pediatric Research, 1978, 12, 980-982.	2.3	17
192	Familial Hypertriglyceridemia in Children: Dietary Management. Pediatric Research, 1977, 11, 953-957.	2.3	7
193	Low and High Density Lipoprotein Cholesterol Interrelationships in Neonates with Low Density Lipoprotein Cholesterol ≤he 10th Percentile and in Neonates with High Density Lipoprotein Cholesterol ≥ the 90th Percentile. Pediatric Research, 1977, 11, 957-959.	2.3	7
194	Plasma cholesterol and triglyceride levels in 6775 school children, ages 6–17. Metabolism: Clinical and Experimental, 1977, 26, 1199-1211.	3.4	117
195	Hyperlipemia in Progeny of Parents. American Journal of Diseases of Children, 1974, 127, 70.	0.5	87
196	Estrogen-induced pancreatitis in patients with previously covert familial Type V hyperlipoproteinemia. Metabolism: Clinical and Experimental, 1972, 21, 657-666.	3.4	110
197	Pediatric familial type II hyperlipoproteinemia: effects of diet on plasma cholesterol in the first year of life. American Journal of Clinical Nutrition, 1972, 25, 224-230.	4.7	48
198	Neonatal familial type II hyperlipoproteinemia: Cord blood cholesterol in 1800 births. Metabolism: Clinical and Experimental, 1971, 20, 597-608.	3.4	154

#	Article	lF	CITATIONS
199	Benign symmetric lipomatosis (launois-bensaude adenolipomatosis) with gout and hyperlipoproteinemia. American Journal of Medicine, 1970, 48, 239-246.	1.5	69